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Abstract
Background: Cytoglobin (Cygb) and neuroglobin (Ngb) are recently identified globin molecules that are expressed
in vertebrate tissues. Upregulation of Cygb and Ngb under hypoxic and/or ischemic conditions in vitro and in vivo
increases cell survival, suggesting possible protective roles through prevention of oxidative damage. We have
previously shown that Ngb is expressed in human glioblastoma multiforme (GBM) cell lines, and that expression of
its transcript and protein can be significantly increased after exposure to physiologically relevant levels of hypoxia.
In this study, we extended this work to determine whether Cygb is also expressed in GBM cells, and whether its
expression is enhanced under hypoxic conditions. We also compared Cygb and Ngb expression in human primary
tumor specimens, including brain tumors, as well as in human normal tissues. Immunoreactivity of carbonic
anhydrase IX (CA IX), a hypoxia-inducible metalloenzyme that catalyzes the hydration of CO2 to bicarbonate, was
used as an endogenous marker of hypoxia.
Results: Cygb transcript and protein were expressed in human GBM cells, and this expression was significantly
increased in most cells following 48 h incubation under hypoxia. We also showed that Cygb and Ngb are
expressed in both normal tissues and human primary cancers, including GBM. Among normal tissues, Cygb and
Ngb expression was restricted to distinct cell types and was especially prominent in ductal cells. Additionally,
certain normal organs (e.g. stomach fundus, small bowel) showed distinct regional co-localization of Ngb, Cygb
and CA IX. In most tumors, Ngb immunoreactivity was significantly greater than that of Cygb. In keeping with
previous in vitro results, tumor regions that were positively stained for CA IX were also positive for Ngb and Cygb,
suggesting that hypoxic upregulation of Ngb and Cygb also occurs in vivo.
Conclusions: Our finding of hypoxic up-regulation of Cygb/Ngb in GBM cell lines and human tumor tissues
suggests that these globin molecules may be part of the repertoire of defense mechanisms that allow cancer cells
to survive in hypoxic microenvironments.
Background
A third member of the vertebrate globin family, neuro-
globin (Ngb), was discovered in 2000 and so-named
because it is primarily expressed in neuronal tissue,
including retina [1]. Shortly thereafter, a fourth verte-
brate globin–cytoglobin (Cygb), was described indepen-
dently by three groups [2-4]. Cygb is expressed
ubiquitously in human tissue [2], however, low cellular
levels of Cygb and Ngb (μM range) may have impeded
their earlier discovery [5]. The amino acid sequences of
Cygb and Ngb show little similarity to that of hemog-
lobin (Hb) or myoglobin (Mb) (< 30% and <25% identity
for Cygb and Ngb, respectively). However, amino acids
that confer Hb and Mb function are conserved together
with all features of the globin fold [2,4,6]. Unlike Hb
and Mb, the physiological roles of Ngb and Cygb are
incompletely understood and several functions are con-
ceivable. Ngb and Cygb may function as a Mb-type
molecule to store O2 thus facilitating O2 diffusion to
mitochondria [1,6,7]. However, the lower O2 affinity of
Ngb (P50 of 7.5 torr under physiological conditions of
pH and temperature) [8] compared to that of Mb (P50
of 2-3 torr) [7] does not support an O2 storage function
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small fraction of Ngb (~ 12%) will be O2 saturated
under normal conditions [5,8-10].
Similar to Mb, but in contrast to Ngb, the O2 binding
of Cygb is pH-independent [8] with higher O2 affinity
values (P50 of 0.7-1.8 torr) [4,8,11], thus suggesting a
possible physiological role to supply O2. However, due
to its low concentration in vivo, Cygb function may be
restricted to O2-requiring cellular reactions unrelated to
mitochondrial respiration [8].
In brain, Ngb is upregulated under hypoxic/ischemic
conditions [12] and may function to scavenge reactive
oxygen (ROS) and nitrogen species (RNS) that are a
major cause of cellular damage [12,13]. It has been
shown that in the Fe
2+-NO form, Ngb reacts more
rapidly with peroxynitrite than does Hb [14]. Addition-
ally, in contrast to Hb and Mb, the reaction of met(Fe
3+)
Ngb with peroxynitrite or hydrogen peroxide does not
appear to generate the cytotoxic ferryl (Fe
4+) species, and
this may contribute to cellular survival [5,14]. However,
evidence for Ngb’s neuroprotective function in vivo is
inconsistent [10,12,13,15-17]. Similarly, Cygb was found
to be upregulated following oxidative stress and hypoxic/
ischemic conditions in vitro and in vivo [17-21], and
overexpression of Cygb in hepatic stellate cells, human
SH-SY5Y neuroblastoma cells and MIN6 cells is protec-
tive [17,22,23]. The function of Cygb has not yet been
intensively investigated. In fibroblasts and related cells
expressing Cygb, its expression has been linked to col-
lagen production and organ fibrosis [24-27]. Recently, it
has been proposed that CYGB may function as a tumor
suppressor gene as hypermethylation of its promoter was
detected in primary human non-small cell lung cancers
(48%) [28] and oral cancers (65%) [29], and in lung (8 of
10) and breast (4 of 4) cancer cell lines [30].
Glioblastoma multiforme (GBM) is the most common
brain tumor among adults comprising 25% of all malig-
nant nervous system tumors. Its resistance to multimod-
ality therapy confers a poor prognosis and the 2-year
survival rate remains only 10-25% [31]. Necrosis, and by
inference hypoxia, is a diagnostic feature of human
GBM tumors [32]. Hypoxic microenvironments fre-
quently occur in human tumors, and tumor cells that
are hypoxic are resistant to ionizing radiation and cer-
tain chemotherapeutic agents, are genetically unstable
and metastasize frequently. Further, hypoxic microenvir-
onments also select for tumor cells with reduced apop-
totic potential. The presence of tumor hypoxia is an
indicator of poor prognosis for both local-regional con-
trol and progression-free survival, and there is also evi-
dence that hypoxia per se selects for a more aggressive
tumor phenotype (reviewed in [33] and references
therein). Tumor cells that survive in hypoxic microen-
vironments must first sense changes in [O2]a n dt h e n
activate defense and adaptation mechanisms [34]. Pre-
vious work suggests that increased Ngb expression may
be part of the repertoire of hypoxia defense mechanisms
in normal brain. Although some studies have reported
that Ngb is expressed exclusively in neurons but not in
glia [35,36], others have reported Ngb expression in
astrocytes cultured from newborn mouse brain [37], and
we have shown that Ngb is expressed and upregulated
by hypoxia in human GBM cell lines [38]. Here, we
examined whether Cygb is also expressed in human
GBM cell lines and tested whether physiologically rele-
vant levels of hypoxia can modulate its expression as
was previously demonstrated for Ngb. In addition to
these in vitro analyses, we used human tissue microar-
rays (TMA) to assess whether Ngb/Cygb is more
broadly expressed among human primary tumors,
including brain cancers, and their adjacent normal
tissues. CA IX immunoreactivity was used as an endo-
genous marker for tissue hypoxia.
Results
Cygb transcript and protein are expressed in GBM cells
in vitro
Cygb mRNA was detected in all aerobic GBM cell lines
(controls), and when cultured under hypoxic conditions
(0.6% O2 × 48 h), all cell lines showed significantly
increased expression of Cygb mRNA (M006x, M010b
and U87T, p < 0.05; M006xLo and M059J, p < 0.001)
(Figure 1). Two cell lines also showed significant
increases in Cygb transcript at earlier time points
(M006xLo at 6 and 24 h, p < 0.001; M059J at 24 h,
p < 0.01). Consistent with qRT-PCR results, Cygb pro-
tein was detected in all aerobic GBM cell lines with
hypoxia-tolerant cells (M006x, M006xLo) showing the
highest basal levels of Cygb. After 48 h of hypoxia, Cygb
protein was significantly increased in four of five cell
lines (M006xLo, M010B, and M059J, p < 0.001; U87 T,
p < 0.01), with the greatest relative increases seen in
hypoxia-sensitive cells M010b and M059J (Figure 2).
Cygb protein was also significantly increased in
M006xLo cells after 24 h of hypoxia (p < 0.01). M006x
cells showed a modest increase in Cygb protein after
hypoxia, but this was not significant (Figure 2A). There
was no correlation between the magnitude of Cygb pro-
tein increase after hypoxia and the respective basal levels
of each cell line.
Cygb and Ngb are expressed in human normal tissues
and cancers
Immunohistochemical staining of TMAs showed that
Ngb and Cygb were variably expressed in both normal
tissues and tumors. As reported previously [39], Ngb
was found primarily in the cytoplasm, whereas Cygb
was detected in both nucleus and cytoplasm. Among
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Page 2 of 16normal tissues, Ngb expression was greatest in bone,
liver, sigmoid colon, rectum and kidney, with low or
negligible levels in skin, muscle and lung (Table 1). Tis-
sues with highest Cygb expression were stomach fundus,
kidney tubules and cerebellum. However, compared to
Ngb, Cygb levels were reduced overall and were low or
absent in approximately half of the tissues. There was
no significant correlation between levels of Cygb and
Ngb protein in these normal tissues (p < 0.07). However,
two features of Cygb and Ngb expression in normal tis-
sues were of particular interest. First, in several normal
tissues, expression of Cygb and Ngb was not uniform
throughout the tissue. Rather, distinct cell types or tis-
sue structures frequently showed strong positive staining
while the remainder of the tissue showed weak or
absent staining. Among the structures strongly stained
for Cygb were ductal cells of the breast and kidney,
secretory cells of the salivary gland, white pulp/lymph of
the spleen, and tips of desquamating cells found in
several types of normal tissue. Ngb staining was also
prominent among ductal cells of breast, endometrium,
testis, prostate and salivary gland. Both Ngb and Cygb
were generally absent from stroma. Second, most nor-
mal tissues showed low or absent CA IX immunoreac-
tivity. However, stomach, small bowel, and gallbladder
showed nearly identical patterns of Ngb, Cygb and CA
IX staining (Figure 3).
Tumor sections showed three distinct staining patterns
for Cygb/Ngb: (1) a uniform expression throughout the
non-stromal tissue; (2) distinct regions of positively stain-
ing cells among otherwise negative or weakly staining tis-
sue; or (3) densely staining focal areas frequently
including intensely positive foci. Among individual
tumor sections included in the ‘tumor/matched normal
tissue’ TMA, Ngb and Cygb expression was generally
increased compared to levels observed in corresponding
normal tissues. As well, Cygb and Ngb immunoreactivity
showed similar patterns of distribution. Most tumor
Figure 1 Cygb mRNA expression in human GBM cells. Cygb mRNA expression was assessed by qRT-PCR after exposure to hypoxia (0.6% O2)
for 0, 6, 24 and 48 h. Data were expressed as fold increase relative to aerobic control (n = 4). (A) M006x: (B) M006xLo; (C) M010B; (D) M059J; (E)
U87T. *p < 0.05; **p < 0.01; ***p < 0.001 (ANOVA).
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eactivity. However, the breast, liver, bladder and thyroid
tumors that contained regions strongly positive for CA
IX also showed in matching sections similar staining
patterns for Cygb and Ngb (Figure 4).
Cygb and Ngb are expressed in human brain tumors
Both Cygb and Ngb were detected in all human brain
tumors, including grades I-IV astrocytomas (Figure 5),
and ependymoblastomas, gangliogliomas and oligoden-
drogliomas (Figure 6). Among low grade astrocytomas
(Grades I and II), Ngb staining intensity was signifi-
cantly greater than that of Cygb (p < 0.05). Grade III
astrocytomas and GBMs also showed relatively greater
Ngb staining but these differences were not significant
(Tables 2 and 3). In tumors that showed distinct pat-
terns of Ngb and Cygb expression, a comparison of
tissue sections showed that these proteins were
expressed in the same regions of the tumor. Large, posi-
tively staining Ngb and Cygb foci were commonly
observed in GBM tumors. Approximately 60% of the
GBM sections were also positive for CA IX staining
which was confined to regions of the tumor also positive
for Cygb and Ngb.
Discussion
Cygb mRNA and protein were detected in five human
GBM cell lines cultured under aerobic conditions. How-
ever, basal Cygb protein levels varied ~19-fold. The
rank-order of Cygb protein expression in these cell lines
Figure 2 Cygb protein expression in human GBM cells. Cygb expression was assessed by Western blot analyses after exposure to hypoxia
(0.6% O2) for 0, 6, 24 and 48 h (n = 4). The integrated intensities of Cygb and a- tubulin (control) bands were determined and expressed in
arbitrary units (AU), and representative blots are shown. (A) M006x: (B) M006xLo; (C) M010B; (D) M059J; (E) U87T. *p < 0.05; **p < 0.01; ***p <
0.001 (ANOVA).
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Page 4 of 16Table 1 Ngb, Cygb and CA IX expression in tissue microarrays of human solid tumors and adjacent normal tissues
Organ NGB CGB CAIX Comments
Normal
Skin 1 1 0 Cygb: + desquamating cells
Breast 1 1 0 Ngb & Cygb: + ductal cells
Spleen 2 1 0
Lymph node 3 1 1 Ngb & Cygb: + white pulp, lymph
Skeletal muscle 0 0 0
Lung 0 0 0
Salivary gland 2 2 1 Ngb & Cygb: + ductal cells
Liver 3 2 1
Gallbladder 2 1 1
Pancreas 3 0 0
Tonsil 2 1 1
Esophagus 2 0 1
Stomach, antrum 2 0 1 Ngb & Cygb: + ductal cells
Stomach, fundus 3 2 2 Ngb & Cygb: + ductal cells
Small bowel 3 1 2 Ngb & Cygb: + ductal cells
Kidney, cortex 3 2 1 Ngb & Cygb: + collecting ducts & tubules; - glomeruli
Kidney, medulla 3 2 1 Ngb & Cygb: + collecting ducts & tubules; - glomeruli
Urinary bladder 3 1 1
Prostate 4 1 1
Testis 1 0 0 Ngb & Cygb: + ductal cells
Uterine cervix 1 1 0 Ngb & Cygb: + desquamating cells, - basal layer
Endometrium 2 0 0 Ngb & Cygb: + ductal cells
Myometrium 2 1 1
Placenta 1 0 0 Ngb & Cygb: + ductal cells
Adrenal gland NE 2 0 Cygb: + ductal cells
Thyroid NE NE NE
Cerebrum 3 3 1
Cerebellum 2 2 1
Tumor
Skin 1 1 1
Skin NE NE NE Ngb & Cygb: indistinguishable from melanin
Subcutis 1 0 0
Breast 4 1 0 Ngb & Cygb: + ductal cells
Breast 3 1 2 Ngb & Cygb: + ductal cells
Hodgkins
lymphoma 3 2 0
Bone 5 0 0
Lung 3 0 0
Lung 2 1 1
Liver 4 2 0
Liver 4 3 2
Liver 5 2 2




Duodenum 1 ?? 0
Sigmoid colon 4 0
Rectum 4 1 Ngb: + ductal cells
Kidney 4 0 Ngb: + villi, - stroma; Cygb:+ normal & tumor cells
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(Continued)
Urinary bladder 1 3 Ngb: + infiltrating cells
Prostate 3 1 Ngb: + ductal cells
Testis 2 0 Ngb: + ductal cells
Uterine cervix 2 1





Tissue microarrays constructed from cores obtained from various human solid tumors and normal adjacent tissues were purchased from IMGENEX Corporation
(San Diego, CA). Immunopositive staining for Ngb, Cygb and CA IX was assessed by two observers who noted the overall tissue staining and the presence of
positively stained focal regions. Each section was assigned an overall score, where 0 = absence of positively stained cells; 1 = a few positive cells/regions ( <
10%); 2 = weak positive staining, occasional positive foci; 3 = intermediate staining, occasional positive foci ( < 50%); 4 = strongly positive in most of the section,
several positive foci; and 5 = strongly positive throughout with many intensely positive foci. Distinct features of the immunostaining patterns in individual tissue
cores are noted in the comments column, where “+” = positive staining, “-” = negative staining and NE = not evaluable.
Figure 3 Expression of Ngb, Cygb and CA IX in human normal tissues. Tissue microarrays containing cores obtained from various human
normal tissues were stained with to antibodies to Ngb, Cygb or CA IX. Positive staining was visualized by the chromogenic reaction of HRP with
DAB. Photomicrographs were obtained at 20× magnification, and the scale bar indicates 50 μM. (A) stomach (fundus); (B) small bowel; (C)
gallbladder.
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tolerant cells having highest Cygb, but lowest Ngb,
levels. We are not aware of any other comparisons of
Cygb/Ngb concentrations in human tumor cell lines.
While our results in GBM cell lines hints at a reciprocal
relationship between Cgyb/Ngb, at least in GBM cell
lines, this would have to be confirmed in a larger study.
Co-expression of Ngb and Cygb has been reported
among various structures of the anterior segment of
human and canine eyes, including the cornea, iris, irido-
corneal angle and the cilliary body [40], and in human
retinal neurons and pigmented epithelium [41]. How-
ever, the relative expression of each protein within spe-
cific cellular structures was not quantified. In the
murine retina, divergent expression of Cygb and Ngb
has been reported, with Ngb levels being significantly
higher [42].
Both Cygb transcript and protein were significantly
increased in four of five GBM cell lines cultured under
conditions that simulate in vivo O2 concentrations
found in the hypoxic regions of human tumors [43,44].
Others have also shown that the hypoxia up-regulates
Cygb transcript and protein in cell lines of neuronal ori-
gin– HN33 [18] and (SH-SY5) [45]. Hypoxia-tolerant
M006x cells that express high basal level of Cygb pro-
tein showed a small, but non-significant, increase in
Cygb after exposure to reduced [O2]. Nonetheless,
M006x cells are hypoxia-responsive as we have shown
that expression of another hypoxia-inducible gene,
VEGF, can be up-regulated at equivalent levels of
Figure 4 Expression of Ngb, Cygb and CA IX in human tumors. Tissue microarrays containing cores obtained from various human tumors
were stained with to antibodies to Ngb, Cygb or CA IX. Positive staining was visualized by the chromogenic reaction of HRP with DAB.
Photomicrographs were obtained at 20× magnification, and the scale bar indicates 50 μM. (A) ovarian carcinoma; (B) hepatocellular carcinoma;
(C) breast infiltrating duct carcinoma.
Emara et al. Cancer Cell International 2010, 10:33
http://www.cancerci.com/content/10/1/33
Page 7 of 16hypoxia [46]. It is interesting to note that while Cygb
levels varied widely among GBM cells under aerobic
condition (19-fold), when exposed to hypoxia, the differ-
ences among the cell lines were notably reduced. This
would suggest that mechanisms exist to allow cells to
titrate intracellular concentrations of Cygb to optimally
meet the demands of given levels of oxidative stress.
In addition to GBM cell lines, Cygb expression was
also observed in both low and high grade human astro-
cytomas, including GBM. To our knowledge, this is the
Figure 5 Expression of Ngb and Cygb in human astrocytomas. Tissue microarrays containing cores obtained from various human brain
tumors were stained with to antibodies to Ngb or Cygb. Positive staining was visualized by the chromogenic reaction of HRP with DAB.
Photomicrographs were obtained at 20× magnification, and the scale bar indicates 50 μM. Sections of representative examples of Grades I-IV
astrocytoma are shown.
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cancers although high Cygb levels have been reported in
brain metastases of two patients with alveolar soft part
sarcomas [47]. Both Cygb transcript and protein have
been reported in normal neurons, but not glia [41]. To
date, there is little information concerning the co-
expression of these two globin molecules in malignant
human tissues. In this study, Ngb protein levels in
Grades I and II astrocytomas were significantly greater
than Cygb levels (p < 0.05). There was also a trend
toward increased Cygb expression as tumor grade
increased from I - IV, however, this would have to be
confirmed in a larger study. A similar pattern of greater
Ngb/Cygb positivity was also observed among non-brain
cancers specimens examined, with Ngb expression sig-
nificantly higher than that of Cygb (p <0.001). Regions
of necrosis are a pathognomonic feature of GBM
tumors, and in many sections, enhanced Cygb/Ngb
staining was observed adjacent to necrotic tissue. The
microenvironment of these perinecrotic regions is likely
to be severely hypoxic and thus, hypoxia-inducible pro-
teins would be expected to be upregulated. In order to
test this, we used CA IX staining as an endogenous
marker of tumor hypoxia. CA IX is a target gene of the
hypoxia-inducible transcription factor, HIF-1a,a n d
some, but not all, studies have shown a correlation
Figure 6 Expression of Cygb and Ngb in human primary brain tumors. Tissue microarrays containing cores obtained from various human
brain tumors were stained with to antibodies to Ngb or Cygb. Positive staining was visualized by the chromogenic reaction of HRP with DAB.
Photomicrographs were obtained at 20× magnification, and the scale bar indicates 50 μM. (A) oligodendroglioma; (B) ependymoblastoma; (C)
ganglioglioma.
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Page 9 of 16Table 2 Ngb, Cygb and CA IX expression in tissue microarrays of human primary brain tumors
Pathology Grade Ngb Cygb CA IX
Astrocytoma of right temporal lobe II 2 1 0
Ganglioglioma of right frontal lobe - 3 1 0
Astrocytoma of left temporal lobe II 3 1 0
Astrocytoma of right frontal lobe I 2 2 0
Astrocytoma II 1 2 0
Astrocytoma I 3 2 0
Astrocytoma of frontal lobe I 3 1 0
Astrocytoma I 3 1 0
Astrocytoma of right temporal lobe II 2 1 0
Astrocytoma of brain I 2 1 0
Astrocytoma of left occipital parietal lobe II 2 3 0
Astrocytoma of right occipital lobe II 3 2 0
Ganglioglioma of left temporoparietal lobe - 3 2 1
Astrocytoma of fourth ventricle II 3 1 1
Astrocytoma of left temporal lobe II 5 2 0
Astrocytoma II 5 2 0
Astrocytoma of left parietal lobe III 3 2 0
Colloid cell hyperplasia of left brain - 5 3 0
Astrocytoma of right temporoparietal lobe III 4 2 0
Astrocytoma of frontal lobe III 3 1 0
Astrocytoma of foramen magnum III 1 0 2
Astrocytoma of left temporal lobe II 3 2 0
Astrocytoma II 3 2 0
Brain tissue - 3 4 1
Astrocytoma of right temporal lobe II 3 2 0
Astrocytoma of fourth ventricle II 3 1 0
Astrocytoma of right temporal lobe II 3 1 0
Astrocytoma III 2 3 0
Astrocytoma of left temporoparietal lobe II 3 2 0
Astrocytoma of right cerebral ventricle II 4 3 0
Oligodendroglioma of right frontal lobe - 4 4 0
Astrocytoma of brain III 4 2 0
Astrocytoma of brain III 3 4 0
Astrocytoma of left temporal lobe II 3 2 0
Astrocytoma of left temporal lobe II 2 2 0
Astrocytoma of intracranial II 3 2 0
Astrocytoma of cerebellum III 1 1 0
Astrocytoma of left temporal lobe III 1 1 0
Astrocytoma with necrosis of left frontal lobe III 3 2 1
Astrocytoma of left temporal lobe III 3 1 0
Astrocytoma of temporoparietal lobe III 4 2 0
Astrocytoma of right cerebelli III 2 2 0
Astrocytoma III 3 2 0
Astrocytoma III 4 4 0
Brain tissue with colloid cell hyperplasia of right temporal lobe - 4 NE 0
Astrocytoma III 2 2 0
Astrocytoma of brain III 2 2 0
Astrocytoma of left frontal lobe III 3 1 0
Astrocytoma of brain II 4 3 0
Astrocytoma of left frontal lobe III 2 1 0
Astrocytoma of left temporal lobe II 4 4 1
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in [48]). In these TMAs, tumor regions that were posi-
tive for CA IX also showed Cygb/Ngb expression. How-
ever, not all regions that were Ngb/Cygb positive also
showed CA IX immunoreactivity. A possible explanation
is the fact that in tumors, CA IX expression is generally
associated with perinecrotic regions that are likely to be
severely hypoxic [48]. In contrast, the up-regulation of
both Ngb and Cygb expression has been observed at
relatively higher O2 tensions (~1% O2).
In addition to the brain tumor TMAs, we also studied
Ngb and Cygb expression in several normal tissues and
their malignant counterparts. Although Cygb has been
described as a ubiquitous cellular globin, it was reduced
or absent from many normal tissues, but prominent in
ductal cells in gallbladder, stomach, small bowel and
kidney. Shigematsu et al. [49] previously reported a
similar distribution for Cgyb in normal tissues. However,
the most striking feature observed in our study was the
distinct regional co-localization of Ngb, Cygb and CA
IX in several normal tissues, including stomach, small
bowel and salivary gland. CA IX expression in human
alimentary tract has been previously described [50], but
to our knowledge, this is the first demonstration of co-
expression of Ngb/Cygb/CA IX in human tissue.
To corroborate these protein expression patterns, we
queried NCBI Gene Expression Omnibus (GEO) Pro-
files–a public repository of microarray gene expression
data [51]. This search indicated that there is robust
expression of Ngb and Cygb mRNA in a variety of
human primary non-malignant and tumor samples
[See Additional files 1 and 2]. However, there is con-
siderable heterogeneity in the expression Ngb and
Cygb mRNA, both within a given histological type of
non-malignant or tumor tissue, and among different
types of tissue.
Table 2 Ngb, Cygb and CA IX expression in tissue microarrays of human primary brain tumors (Continued)
Astrocytoma of left occipital III 3 3 0
Astrocytoma of left temporal lobe III 4 4 0
Astrocytoma of right temporal lobe IV 3 4 0
Astrocytoma of left temporal lobe III 2 1 0
Astrocytoma of right temporal lobe III 1 1 0
Astrocytoma of right temporal lobe III 3 1 0
Astrocytoma of fourth ventricle IV 3 2 0
Astrocytoma II 3 3 0
Astrocytoma of temporal lobe IV 4 2 0
Tumor necrosis tissue of right frontal region - 4 5 1
Astrocytoma of left occipital parietal lobe III 4 5 1
Malignant oligodendroglioma - 2 2 0
Desmoplastic astrocytoma of left temporoparietal lobe - 3 5 0
Astrocytoma of intracranial II 3 2 0
Ependymoblastoma of posterior fossa - 3 2 0
Ependymoma of brain parietooccipital - 3 3 0
Ependymoma of brain - 3 2 0
Ependymoma of right parietal lobe - 4 4 0
Ependymoma of intracranial - 3 3 0
Matched cerebrum tissue of 1st tumor - 2 2 0
Matched cerebrum tissue of 2nd tumor - 3 3 0
Matched cerebrum tissue of 3rd tumor - 4 4 1
Matched cerebrum tissue of 4th tumor - 1 2 0
Normal cerebrum tissue - 1 2 0
Normal cerebrum tissue - 1 1 0
Normal cerebrum tissue - 5 2 0
Normal cerebrum tissue - 2 3 0
Normal cerebrum tissue - 3 4 0
Normal cerebellum tissue - 3 1 0
Tissue microarrays constructed from cores obtained from various human primary brain cancers and normal adjacent brain were purchased from IMGENEX
Corporation (San Diego, CA). Immunopositive staining for Ngb, Cygb and CA IX was assessed by two observers who noted the overall tissue staining and the
presence of positively stained focal regions. Each section was assigned an overall score, where 0 = absence of positively stained cells; 1 = a few positive cells/
regions ( < 10%); 2 = weak positive staining, occasional positive foci; 3 = intermediate staining, occasional positive foci ( < 50%); 4 = strongly positive in most of
the section, several positive foci; and 5 = strongly positive throughout with many intensely
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decade ago, their functions continue to be explored.
Currently, evidence from both in vitro and in vivo
model systems indicates that these globins play impor-
tant roles in protecting cells from death during ischemic
insult (hypoxia-reperfusion), oxygen/glucose deprivation,
or exogenous oxidative stress [17,22,45,52-55]. Recently,
Raychaudhuri et al. [56] used experimental and compu-
tational analyses to show that Ngb overexpression pro-
tects SH-SY5Y neuroblastoma cells from cell death by
inhibiting the initiation of the intrinsic apoptotic path-
way. They hypothesize that the ability of Ngb to bind to
cytochrome c provides a mechanism whereby Ngb could
interfere with cytochrome c-induced activation caspase-
9, a critical step required for initiation of the intrinsic
apoptotic cascade. Accordingly, Ngb or Cygb expression
m a yp r o v i d et h es a m ep r o - s u r v i v a le f f e c ti nt u m o r si n
which both chronic and intermittent hypoxia (ischemia/
reperfusion) as well as glucose deprivation commonly
occur (reviewed in [33].
Conclusions
We showed two novel globins–Cygb and Ngb, are
expressed in human primary tumors and cell lines. Their
up-regulation by hypoxia in vitro, and their association
with an endogenous hypoxia marker in tumor tissue
Table 3 Assessment of Cygb, Ngb and CA IX expression
in tissue microarrays of human glioblastoma multiforme
tumors
Pathology Grade Ngb Cygb CA IX
Glioblastoma IV 3 1 1
Glioblastoma IV 3 1 1
Pleomorphic glioblastoma IV 5 4 1
Pleomorphic glioblastoma IV 5 4 1
Glioblastoma IV 3 1 2
Glioblastoma IV 2 1 1
Pleomorphic glioblastoma IV 5 2 2
Pleomorphic glioblastoma IV 5 2 2
Glioblastoma IV 2 2 1
Glioblastoma IV 2 2 1
Glioblastoma (sparse) IV 2 2 0
Glioblastoma (necrotic tissue) IV 4 5 1
Glioblastoma (necrotic tissue) IV 4 5 1
Pleomorphic glioblastoma IV 4 3 0
Pleomorphic glioblastoma IV 4 3 0
Glioblastoma III 2 2 0
Glioblastoma III 2 2 0
Glioblastoma IV 2 3 1
Glioblastoma IV 3 2 1
Glioblastoma IV 3 2 1
Glioblastoma III 5 4 0
Glioblastoma III 5 4 0
Glioblastoma IV 5 2 1
Glioblastoma IV 5 2 2
Glioblastoma IV 4 2 0
Glioblastoma IV 5 2 1
Glioblastoma IV 5 2 3
Glioblastoma IV 3 2 0
Glioblastoma IV 3 3 1
Glioblastoma IV 4 3 0
Glioblastoma IV 4 2 2
Glioblastoma IV 4 2 0
Glioblastoma IV 3 2 0
Glioblastoma III 5 2 0
Glioblastoma III 5 3 1
Glioblastoma IV 4 2 3
Glioblastoma IV 4 2 0
Glioblastoma IV 5 2 0
Pleomorphic glioblastoma IV 4 2 1
Pleomorphic glioblastoma IV 4 3 2
Glioblastoma III 4 3 2
Glioblastoma III 4 3 2
Glioblastoma III 4 2 0
Glioblastoma III 4 3 0
Glioblastoma IV 4 4 0
Glioblastoma IV 5 3 0
Glioblastoma IV 4 3 0
Pleomorphic glioblastoma IV 5 4 1
Pleomorphic glioblastoma IV 5 4 1
Table 3 Assessment of Cygb, Ngb and CA IX expression
in tissue microarrays of human glioblastoma multiforme
tumors (Continued)
Glioblastoma III 3 2 0
Glioblastoma III 3 2 0
Glioblastoma IV 4 3 3
Glioblastoma IV 4 3 3
Glioblastoma IV 4 4 0
Glioblastoma IV 3 2 0
Glioblastoma IV 4 3 0
Glioblastoma IV 3 4 0
Glioblastoma IV 3 4 0
Glioblastoma IV 2 3 0
Glioblastoma IV 3 2 0
Adjacent normal brain - 4 3 0
Adjacent normal brain - 3 2 1
Adjacent normal brain - 3 4 0
Tissue microarrays constructed from cores obtained from various human
glioblastoma miltiforme tumors and normal adjacent brain were purchased
from IMGENEX Corporation (San Diego, CA). Immunopositive staining for Ngb,
Cygb and CA IX was assessed by two observers who noted the overall tissue
staining and the presence of positively stained focal regions. Each section was
assigned an overall score, where 0 = absence of positively stained cells; 1 = a
few positive cells/regions ( < 10%); 2 = weak positive staining, occasional
positive foci; 3 = intermediate staining, occasional positive foci ( < 50%); 4 =
strongly positive in most of the section, several positive foci; and 5 = strongly
positive throughout with many intensely positive foci. NE = not evaluable.
Emara et al. Cancer Cell International 2010, 10:33
http://www.cancerci.com/content/10/1/33
Page 12 of 16sections suggests that these globins may contribute to the
pro-survival mechanisms utilized by these cancers to sur-
vive under conditions of oxidative stress.
Methods
Cell lines and in vitro culture conditions
The origin and characterization of the GBM cell lines
have been published previously: the M059J (ATCC num-
ber CRL2366) and M010b cell lines are hypoxia-sensitive;
the M006x and M006xLo cell lines are hypoxia-tolerant
[46,57,58]. The U87T cell line was established following
serial in vivo selection in a glioma mouse model [59] and
w a sk i n d l yp r o v i d e db yD r .D o n n aS e n g e r( U n i v e r s i t yo f
Calgary). Its relative sensitivity to hypoxia has not been
determined. All cells were maintained as monolayer cul-
tures in DMEM/F12 media supplemented with 10% fetal
calf serum and 1 mM L-glutamine in a humidified
atmosphere of 5% CO2 in air at 37°C. All tissue culture
supplies were purchased from GIBCO.
Generation of hypoxia in vitro
A de-gassing manifold was used to generate hypoxia
in vitro [60]. Exponential phase cells (~2 × 10
5)w e r e
seeded onto 60-mm glass plates and then incubated
under standard laboratory culture conditions (5% CO2
in air) for 4 days. The medium was then replenished
and the plates were transferred to aluminum chambers
from which the air was evacuated and then replaced
with 5% CO2/balance N2 until an O2 tension of 0.6%
was achieved. The sealed, air-tight aluminum chambers
were then incubated at 37°C for 6-48 h. At the end of
each incubation interval, the aluminum chambers were
unsealed, the tissue culture plates removed, RNA and
protein isolated from the cells as described in Section
2.4 and 2.5.
Quantitative real-time reverse transcription-PCR
Total RNA from cultured cell lines was isolated using
the RNeasy mini kit (QIAGEN). Reverse transcription
(RT) was carried out with 1 μgt o t a lR N A .p e r2 0m l
reaction volume using QuantiTect reverse transcription
kit (QIAGEN). RT experiments were performed with
GeneAmp PCR system 9700 (Applied Biosystems).
Quantitative real-time PCR (qRT-PCR) analysis was per-
formed with a 7900 HT Fast Real-Time PCR System
(Applied Biosystems) using TaqMan fast universal PCR
master mix and a validated TaqMan Gene Expression
assay (Applied Biosystems) for the human CYGB gene
(assay ID: Hs00370478_ml). Human 18 S rRNA gene
(part no.: 4333760T, Applied Biosystems) was used as
endogenous control. Amplification data were analyzed
with SDS RQ Manager 1.2. Relative quantities of Cygb
transcripts were normalized against relative quantities of
the 18 S rRNA transcripts, and fold-expression changes
calculated using the expression 2
-ΔΔCT.
Western blotting
Whole-cell lysates were prepared using complete Lysis-
M buffer (Roche Diagnostics) and protein content deter-
mined using a protein assay kit (Pierce). Equal amounts
of protein (50 μg) were resolved using 13% SDS -PAGE
under reducing condition and electro-transferred to
polyvinylidene difluoride membranes (Bio-Rad Labora-
tories, CA). Membranes were blocked with 5% skim
milk then incubated with Cygb antibody (1:60 rabbit
anti-human polyclonal antibody [sc-66855] Santa Cruz
Biotechnology, Inc, CA) or a-tubulin antibody (1:5000,
mouse anti-human a-tubulin monoclonal antibody,
SIGMA) as loading control. Membranes were incubated
with polyclonal goat anti-rabbit IgG (H+L) horseradish
peroxidase (HRP)-conjugated (1:25000, Jackson Immu-
noResearch Laboratories, Inc. PA) or polyclonal goat
anti-mouse IgG HRP-conjugated (1:6000, DakoCytoma-
tion Denmark A/S, Demark). Bound proteins were
detected using chemiluminescence reagents (SuperSignal
West Pico Chemiluminescent Substrate, Thermo Scien-
tific, IL) and visualized by exposing to X-ray film (Fuji
Photo Film, Japan) that was developed using a Kodak X-
OMAT 2000A processor (Eastman Kodak Company,
Japan). X-ray films were scanned using an Artixscan
1800f scanner (MICROTEK, TAIWAN) and bands were
analyzed using Quantity One 1-D analysis software (Bio-
Rad Laboratories). The integrated areas of bands were
determined and expressed in arbitrary units (AU).
Tissue micorarrays and immunostaining
Tissue microarrays (TMA) constructed from tissue sec-
tions obtained from various human solid tumors and
normal adjacent tissues (IMH-346), GBMs (IMT-01256),
and various brain cancers and normal adjacent tissues
(IMT-01257) were purchased from IMGENEX Corpora-
tion (San Diego, CA). The manufacturer confirmed the
glial origin of the brain tumors included on the arrays
using immunoreactivity to anti-glial fibrillary acid pro-
tein. Immunohistochemical staining was performed
according to manufacturer’s protocol with modifications.
TMA slides were deparaffinized by incubating in a dry
oven at 62°C for 1.5 h, dewaxed in xylene, and then
hydrated. TMAs were processed for antigen retrieval,
incubated with blocking buffer (0.5 M glycine in PBS-
0.2% brij35) and then with antibodies to Ngb (1:150,
mouse anti-human Ngb monoclonal antibody, BioVen-
dor Laboratory Medicine Inc., Czech Republic), Cygb
(1:150, mouse anti-human Cygb monoclonal antibody,
Abnova Corporation, Taiwan) or Ca IX (1:600, rabbit
anti-human CA IX, Novus Biologicals, Inc., USA). The
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by using Cygb or Ngb peptides to block positive immu-
nostaining [Additional file 3]. Tissue endogenous peroxi-
dase was quenched by incubation with 3% H2O2 for
15 min. Tissue sections were incubated with HRP-con-
jugated goat anti-mouse antibodies (DakoCytomation)
and positive staining visualized by the chromogenic
reaction of HRP with DAB (3,3’ diaminobenzidine tetra-
hydrochloride) (DakoCytomation). Relative Cygb and
Ngb expression in each tissue core was assessed by two
observers who noted the overall tissue staining and the
presence of positively stained focal regions. Each section
was assigned an overall score, where 0 = absence of
positively stained cells; 1 = a few positive cells/regions
(< 10%); 2 = weak positive staining, occasional positive
foci; 3 = intermediate staining, occasional positive foci
(< 50%); 4 = strongly positive in most of the section,
several positive foci; and 5 = strongly positive through-
out with many intensely positive foci.
Statistics
Data from four replicate experiments were expressed as
mean ± standard error. Statistical analyses were per-
formed using SigmaPlot 11 software (Systat Software,
Inc). Differences between groups were compared using
one-way ANOVA or ANOVA on ranks (Kruskal-Wallis)
based on the normality and equal variance tests. To
determine exactly which groups are different and the
size of the difference, multiple comparisons versus con-
trol group were carried out using Bonferroni t-test and
Dunnett’so rD u n n ’s test for one-way ANOVA and
ANOVA on ranks (Kruskal- Wallis), respectively, as
post-hoc tests.
Additional material
Additional file 1: Table S1. Results of GEO profiles query of Cygb
expression in human non-malignant and tumor tissues. This table
provides the range of the intra-sample percentile rank values for Cygb
expression in a variety of human primary tissue samples. These values
provide an indication of the relative expression of Cygb compared to
that of all other genes expressed in that sample.
Additional file 2: Table S2. Results of GEO profiles query of Ngb
expression in human non-malignant and tumor tissues. This table
provides the range of the intra-sample percentile rank values for Ngb
expression in a variety of human primary tissue samples. These values
provide an indication of the relative expression of Ngb compared to that
of all other genes expressed in that sample.
Additional file 3: Figure S1. Antibody specificity demonstrated by
competitive immunostaining. This figure shows that incubation of
primary Ngb and Cygb antibodies with the relevant recombinant
proteins effectively blocked positive immunostaining.
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